作者: Cao, Yiming ; Huang, Weijin ; Wang, Xin ; Yang, Jing ; Sang, Ye ; Yu, Changxiao ; Lu, Haitao ; Fang, Jiaxin ; Liu, Fan ; Mai, Jierui ; Long, Jinrong ; Sun, Huisheng ; Miao, Yiqi ; Wang, Shengqi ; Zhang, Zhen ; Wang, Youchun

Monkeypox has been declared a public health emergency by the World Health Organization. There is an urgent need for efficient and safe vaccines against the monkeypox virus (MPXV) in response to the rapidly spreading monkeypox epidemic. In the age of COVID-19, mRNA vaccines have been highly successful and emerged as platforms enabling rapid development and large-scale preparation. Here, we develop two MPXV quadrivalent mRNA vaccines, named mRNA-A-LNP and mRNA-B-LNP, based on two intracellular mature virus specific proteins (A29L and M1R) and two extracellular enveloped virus specific proteins (A35R and B6R). By administering mRNA-A-LNP and mRNA-B-LNP intramuscularly twice, mice induce MPXV specific IgG antibodies and potent vaccinia virus (VACV) specific neutralizing antibodies. Further, it elicits efficient MPXV specific Th-1 biased cellular immunity, as well as durable effector memory T and germinal center B cell responses in mice. In addition, two doses of mRNA-A-LNP and mRNA-B-LNP are protective against the VACV challenge in mice. And, the passive transfer of sera from mRNA-A-LNP and mRNA-B-LNP-immunized mice protects nude mice against the VACV challenge. Overall, our results demonstrate that mRNA-A-LNP and mRNA-B-LNP appear to be safe and effective vaccine candidates against monkeypox epidemics, as well as against outbreaks caused by other orthopoxviruses, including the smallpox virus.

2021-03-01·Molecular Therapy1区 · 医学

Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines

1区 · 医学

Review

作者: Moghimi, S Moein

Mortality from coronavirus disease 2019 (COVID-19) in populations at high risk,such as the elderly, certain ethnic groups (e.g., Black/African American, and Hispanic/Latino persons), obese individuals, and those with endothelial dysfunction is substantial.While treatment options are limited, vaccination against SARS-CoV-2, the virus that causes COVID-19, is the most important global strategy in controlling the pandemic.Thus, two lipid nanoparticle (LNP)-based mRNA vaccines (Pfizer-Bio-NTech and Moderna) against SARS-CoV-2 have already received emergency use authorization by the US Food and Drug Administration (FDA).Anaphylaxis can occur after exposure to different allergens (e.g., food ingredients, venom, and drugs), but anaphylaxis after vaccination is rare and, in some vaccine recipients, not even related to the vaccine components.LNPs and other excipients are possible sources of allergens.

100 项与 mRNA-A-LNP(Chinese PLA Academy of Military Medical Sciences) 相关的药物交易

登录后查看更多信息